Vectibix is the first entirely human monoclonal antibody for the treatment of patients with epidermal growth factor receptor- (EGFr) expressing metastatic colorectal cancer after disease ...

Home Stocks Amgen-stock News for Amgen LUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer ...

Vectibix was approved in the U.S. in September 2006 as a monotherapy for the treatment of patients with EGFR-expressing mCRC after disease progression after prior treatment with fluoropyrimidine ...

However, trends were observed favoring both the 960-mg Lumakras/Vectibix arm and the 240-mg Lumakras Vectibix arm vs the SOC arm. In total, treatment-related side effects occurred in 94.3% (50 ...

These new data show that combining LUMAKRAS™ (sotorasib) with Vectibix® (panitumumab), Amgen 's monoclonal antibody epidermal growth factor receptor (EGFR) inhibitor, demonstrated encouraging ...

Vectibix was approved in the United States in September 2006 as a monotherapy for the treatment of patients with EGFR expressing mCRC after disease progression on or following fluoropyrimidine ...

Vectibix was approved in the United States in September 2006 as a monotherapy for the treatment of patients with EGFR expressing mCRC after disease progression on or following fluoropyrimidine ...

Amgen Inc. AMGN -0.10% will take back rights to osteoporosis drug Prolia and cancer drugs Xgeva and Vectibix under a deal with GlaxoSmithKline PLC. GSK -2.26% Financial terms weren’t disclosed.

For more information call (800) 772-6436 or visit www.vectibix.com.

Amgen Inc.’s Vectibix, a drug for colon cancer, may be useful to even fewer patients who suffer from that illness than scientists previously found, according to a company-funded study of gene ...

Erbitux, Vectibix Label Change Approved for KRAS Gene By Shirley S. Wang July 20, 2009 10:27 am ET Resize ...

SAN FRANCISCO (MarketWatch) -- Amgen Inc. late Thursday said that it has discontinued a clinical trial evaluating the addition of its drug Vectibix to a treatment regiment of chemotherapy and the ...